Literature DB >> 15890935

Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.

Paolo Lusso1, Patricia L Earl, Francesca Sironi, Fabio Santoro, Chiara Ripamonti, Gabriella Scarlatti, Renato Longhi, Edward A Berger, Samuele E Burastero.   

Abstract

The external subunit of the human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (Env), gp120, contains conserved regions that mediate sequential interactions with two cellular receptor molecules, CD4 and a chemokine receptor, most commonly CCR5 or CXCR4. However, antibody accessibility to such regions is hindered by diverse protective mechanisms, including shielding by variable loops, conformational flexibility and extensive glycosylation. For the conserved neutralization epitopes hitherto described, antibody accessibility is reportedly unrelated to the viral coreceptor usage phenotype. Here, we characterize a novel, conserved gp120 neutralization epitope, recognized by a murine monoclonal antibody (MAb), D19, which is differentially accessible in the native HIV-1 Env according to its coreceptor specificity. The D19 epitope is contained within the third variable (V3) domain of gp120 and is distinct from those recognized by other V3-specific MAbs. To study the reactivity of MAb D19 with the native oligomeric Env, we generated a panel of PM1 cells persistently infected with diverse primary HIV-1 strains. The D19 epitope was conserved in the majority (23/29; 79.3%) of the subtype-B strains tested, as well as in selected strains from other genetic subtypes. Strikingly, in CCR5-restricted (R5) isolates, the D19 epitope was invariably cryptic, although it could be exposed by addition of soluble CD4 (sCD4); epitope masking was dependent on the native oligomeric structure of Env, since it was not observed with the corresponding monomeric gp120 molecules. By contrast, in CXCR4-using strains (X4 and R5X4), the epitope was constitutively accessible. In accordance with these results, R5 isolates were resistant to neutralization by MAb D19, becoming sensitive only upon addition of sCD4, whereas CXCR4-using isolates were neutralized regardless of the presence of sCD4. Other V3 epitopes examined did not display a similar divergence in accessibility based on coreceptor usage phenotype. These results provide the first evidence of a correlation between HIV-1 biological phenotype and neutralization sensitivity, raising the possibility that the in vivo evolution of HIV-1 coreceptor usage may be influenced by the selective pressure of specific host antibodies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15890935      PMCID: PMC1112133          DOI: 10.1128/JVI.79.11.6957-6968.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

1.  The discovery of HIV as the cause of AIDS.

Authors:  Robert C Gallo; Luc Montagnier
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

2.  Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D.

Authors:  Robyn L Stanfield; Miroslaw K Gorny; Constance Williams; Susan Zolla-Pazner; Ian A Wilson
Journal:  Structure       Date:  2004-02       Impact factor: 5.006

3.  The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

Authors:  Miroslaw K Gorny; Kathy Revesz; Constance Williams; Barbara Volsky; Mark K Louder; Christopher A Anyangwe; Chavdar Krachmarov; Samuel C Kayman; Abraham Pinter; Arthur Nadas; Phillipe N Nyambi; John R Mascola; Susan Zolla-Pazner
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

4.  CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue.

Authors:  J C Grivel; L B Margolis
Journal:  Nat Med       Date:  1999-03       Impact factor: 53.440

5.  Conformational changes in env oligomer induced by an antibody dependent on the V3 loop base.

Authors:  Lisa Cavacini; Mark Duval; Leslie Song; Rebecca Sangster; Shi-hua Xiang; Joseph Sodroski; Marshall Posner
Journal:  AIDS       Date:  2003-03-28       Impact factor: 4.177

6.  HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use.

Authors:  Ingrid Karlsson; Liselotte Antonsson; Yu Shi; Anders Karlsson; Jan Albert; Thomas Leitner; Björn Olde; Christer Owman; Eva Maria Fenyö
Journal:  AIDS       Date:  2003-12-05       Impact factor: 4.177

7.  Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses.

Authors:  Steven M Wolinsky; Ronald S Veazey; Kevin J Kunstman; Per Johan Klasse; Jason Dufour; Andre J Marozsan; Martin S Springer; John P Moore
Journal:  Virology       Date:  2004-10-10       Impact factor: 3.616

8.  Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage.

Authors:  D Cecilia; V N KewalRamani; J O'Leary; B Volsky; P Nyambi; S Burda; S Xu; D R Littman; S Zolla-Pazner
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

9.  Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.

Authors:  Mark A Jensen; Fu-Sheng Li; Angélique B van 't Wout; David C Nickle; Daniel Shriner; Hong-Xia He; Sherry McLaughlin; Raj Shankarappa; Joseph B Margolick; James I Mullins
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1.

Authors:  C Spenlehauer; S Saragosti; H J Fleury; A Kirn; A M Aubertin; C Moog
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more
  50 in total

1.  Solution structure, conformational dynamics, and CD4-induced activation in full-length, glycosylated, monomeric HIV gp120.

Authors:  Miklos Guttman; Maria Kahn; Natalie K Garcia; Shiu-Lok Hu; Kelly K Lee
Journal:  J Virol       Date:  2012-06-06       Impact factor: 5.103

2.  Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds.

Authors:  Kazuhisa Yoshimura; Shigeyoshi Harada; Junji Shibata; Makiko Hatada; Yuko Yamada; Chihiro Ochiai; Hirokazu Tamamura; Shuzo Matsushita
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

3.  Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization.

Authors:  Emma T Crooks; Penny L Moore; Douglas Richman; James Robinson; Jeffrey A Crooks; Michael Franti; Norbert Schülke; James M Binley
Journal:  Hum Antibodies       Date:  2005

Review 4.  HIV and the chemokine system: 10 years later.

Authors:  Paolo Lusso
Journal:  EMBO J       Date:  2006-01-26       Impact factor: 11.598

5.  Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching.

Authors:  Cristina Pastore; Rebecca Nedellec; Alejandra Ramos; Oliver Hartley; John L Miamidian; Jacqueline D Reeves; Donald E Mosier
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

6.  A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer.

Authors:  Shi-Hua Xiang; Andrés Finzi; Beatriz Pacheco; Kevin Alexander; Wen Yuan; Carlo Rizzuto; Chih-Chin Huang; Peter D Kwong; Joseph Sodroski
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

7.  Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.

Authors:  Xueling Wu; Anna Sambor; Martha C Nason; Zhi-Yong Yang; Lan Wu; Susan Zolla-Pazner; Gary J Nabel; John R Mascola
Journal:  Virology       Date:  2008-09-18       Impact factor: 3.616

8.  Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.

Authors:  Evelien M Bunnik; Esther D Quakkelaar; Ad C van Nuenen; Brigitte Boeser-Nunnink; Hanneke Schuitemaker
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

9.  Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4.

Authors:  Gregory Q Del Prete; Beth Haggarty; George J Leslie; Andrea P O Jordan; Josephine Romano; Nathaniel Wang; Jianbin Wang; Michael C Holmes; David C Montefiori; James A Hoxie
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

Review 10.  Molecular mechanisms of FIV infection.

Authors:  John H Elder; Magnus Sundstrom; Sohela de Rozieres; Aymeric de Parseval; Chris K Grant; Ying-Chuan Lin
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.